477 related articles for article (PubMed ID: 34907813)
1. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
3. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
4. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
Eldhagen P; Lehtonen J; Gude E; Gustafsson F; Bagger-Bahnsen A; Vakevainen M; Pilgaard T; Wedell-Wedellsborg D; Poulsen SH;
ESC Heart Fail; 2023 Jun; 10(3):1871-1882. PubMed ID: 36946241
[TBL] [Abstract][Full Text] [Related]
7. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
[TBL] [Abstract][Full Text] [Related]
8. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
[TBL] [Abstract][Full Text] [Related]
9. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
10. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial.
Reaney M; Addepalli P; Allen V; Spertus JA; Dolan C; Sehnert AJ; Fine JT
Pharmacoecon Open; 2022 Jul; 6(4):575-586. PubMed ID: 35718845
[TBL] [Abstract][Full Text] [Related]
12. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
[TBL] [Abstract][Full Text] [Related]
13. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
[TBL] [Abstract][Full Text] [Related]
14. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
[TBL] [Abstract][Full Text] [Related]
16. Patient reported outcomes in obstructive hypertrophic cardiomyopathy undergoing myectomy: Results from SPIRIT-HCM study.
Tower-Rader A; Szpakowski N; Popovic ZB; Bittel B; Fava A; Ospina S; Xu B; Thamilarasan M; Mentias A; Smedira NG; Desai MY
Prog Cardiovasc Dis; 2023; 80():66-73. PubMed ID: 37302651
[TBL] [Abstract][Full Text] [Related]
17. Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study.
Kuan WC; Chee KH; Kasim S; Lim KK; Dujaili JA; Lee KK; Teoh SL
J Med Econ; 2024; 27(1):607-617. PubMed ID: 38557412
[TBL] [Abstract][Full Text] [Related]
18. A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.
Burstein Waldman C; Owens A
Future Cardiol; 2021 Oct; 17(7):1269-1275. PubMed ID: 34018809
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
Dong T; Nissen S; Ospina S; Desai MY
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
[TBL] [Abstract][Full Text] [Related]
20. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
